The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
AstraZeneca partners with American Summit Therapeutics to acquire a license for the lung cancer drug ivonescimab worth $15 billion.
Jul 05, 2025•12 months ago
Contract Type
partnership
Cambridge
Description
AstraZeneca is negotiating a partnership agreement with American Summit Therapeutics to acquire a license for the lung cancer treatment ivonescimab for $15 billion. The deal may include upfront and phased payments, marking a significant collaboration in biopharmaceutical innovations.
Company Information
Company
British biopharma company
Location
Cambridge, Massachusetts, United States
About
A British biopharmaceutical company focused on developing new therapies and treatments for various diseases. The company is known for its expertise in drug development and innovative approaches to healthcare. It aims to address unmet medical needs through advanced biopharmaceutical solutions. Details on its specific operations or pipeline are not provided in the current context.
Cambridge